Summary
65 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 44% a year over the last 3 years.
- You pay 15.6 USD for 1 USD of yearly profit, little for its sector.
What to watch
- Earnings per share swing sharply from year to year.
- For every 100 USD of shareholders' equity it carries 154 USD of debt.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedPrice against the Bulios Fair Price
P/E against the industry (Drug Manufacturers - Specialty & Generic)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 15.6 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 16% a year. Earnings per share grew by 44% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 66 USD
- Sales and administration 21 USD
- Taxes and other 6.5 USD
- Net profit 6.6 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 1.0 USD
Out of every 100 USD of revenue, 6.6 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 60.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 1.25%
- Paid out of profit
- 20%
You receive $0.48 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 4
- Sell 4
Today's price within the analysts' price targets
The average target of $28 is 27% below today's price. 43% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
- Vaccines 100%
By region
- UNITED STATES 58%
- Latin America and Canada 22%
- EMEA 12%
- Asia Pacific 7.4%
Vaccines brings in 100% of revenue.
Segments in detail